Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

[1]  P. Neven,et al.  Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Vincent-Salomon,et al.  Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS. , 2022, Analytical chemistry.

[3]  I. Bièche,et al.  Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1 , 2022, BMJ Open.

[4]  A. Schneeweiss,et al.  Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. , 2021, JAMA oncology.

[5]  A. Bardia,et al.  ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer , 2021, Breast cancer research : BCR.

[6]  H. Burstein.  Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. , 2020, The New England journal of medicine.

[7]  M. Dowsett,et al.  ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials , 2020, Clinical Cancer Research.

[8]  F. Bidard,et al.  ESR1 mutations: a new biomarker in breast cancer , 2019, Expert review of molecular diagnostics.

[9]  A. Vincent-Salomon,et al.  A single droplet digital PCR for ESR1 activating mutations detection in plasma , 2019, bioRxiv.

[10]  Henry W. Long,et al.  Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. , 2018, Cancer cell.

[11]  M. Goetz,et al.  MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[13]  E. Winer,et al.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.

[14]  M. Dowsett,et al.  Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[16]  Corneel Coens,et al.  Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial , 2010, The Lancet.